Table 3 Overview of demographic and clinical information collected

Basics

Sample size

997

Patients consented

531

Number of variables

21

Involvement in clinical trial

Yes, No

Demographics

Age

Gender

Male, Female

Ethnicity

Inclusion in Clinical Trial

Yes, No

Comorbidities

Hypertension, Diabetes, Other cancer, Hypercholesterolaemia, Respiratory disease, Cardiovascular disease, Chronic Kidney Disease, Psychiatric Disorder

Smoking

Yes, No, Unknown

Bladder cancer characteristics

Diagnosis

New, Recurrent

Histology

Urothelial Cell Carcinoma, Papillary Urothelial Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Micropapillary variant, Plasmacytoid variant, Paraganglioma, Papilloma, Small cell carcinoma, Sarcomatoid, Unknown

Grade

G1, G2, G3

TNM stage

Lymphovascular invasion

Yes, No

TURBT

Yes, No

Surgery

Cystoprostatectomy, Cystectomy, Nephrouretectomy, Uretectomy, Nephrouretectomy and cystoprostatectomy, Cystectomy and ureterectomy, Diverticulectomy, Nephrouretectomy and cystectomy, Nephrouretectomy and partial cystectomy, Ureterostomy, Urethrectomy, Exenteration, None

Chemotherapy

Neoadjuvant, Adjuvant, Chemotherapy, Palliative, Neoadjuvant and adjuvant, None

Radiotherapy

Yes, No

Intravesical therapy

Di Stasi, BCG, Mitomycin, BCG and mitomycin in different occasions, Di Stasi and mitomycin in different occasions, Other, None

Intravesical therapy failure

Yes, No

Laser ablation

Yes, No

Immunotherapy

Yes, Poorly tolerated, Unknown, No, Not Applicable